speb/financial-data huggingface dataset:
TORNTPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 474000000.00
TORNTPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 1587100000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 10269900000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 16407500000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 338445440.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Special Income Charges: 170600000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 61980700000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 7710600000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 119181630.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Tax Provision: 6019300000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.33
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 1042400000.00
TORNTPHARM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -3980700000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 150118500000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 86942900000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 53685600000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 61980700000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Total Expenses: 73236700000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 88137800000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 96981300000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 33664800000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 12000000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 313100000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 365700000.00
TORNTPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 365700000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1164700000.00
TORNTPHARM.NS balance_sheet (annual, 2023-03-31) — Working Capital: -1335800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 52022300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 105623100000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 20893200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 18443000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -20315800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 714300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -112100000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Amortization: 5429200000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 5429200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 332900000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 338445440.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Basic EPS: 48.94
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 5085300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 16111300000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -4327800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 845200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 8351400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 10040000000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -10153400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 3992900000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 4358500000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -494300000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -175800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Payable: 4135500000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 715400000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 4180800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 3185400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 68561500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 2961800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 27877300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 56114800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 200600000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 23336400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 23537000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 54252500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 4001400000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation: 2523800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 7953000000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 7953000000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 2523800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Derivative Product Liabilities: 2400000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 338445440.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 48.94
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 16563800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 38600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — EBIT: 27047400000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — EBITDA: 35000400000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 80700000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 8351400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Financial Assets: 43800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -27796400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 14339500000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 28333000000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -179900000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 200000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 7722800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill: 3380300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 49208500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 18555100000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 56247300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Gross Profit: 77745800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 251600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 129700000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense: 3526300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 3526300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Interest Income: 114800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 114800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -3709600000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 131200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Inventory: 22790700000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 107935700000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -1679000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 332900000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 0.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 7797500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 644600000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 16037800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 16682400000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 0.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -12360100000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 4446900000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 26530600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: 0.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Net Debt: 31022800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -570900000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Income: 16563800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 16563800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 16563800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 16563800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 16563800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 23521100000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 16563800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Interest Income: -3420800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 1181000000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -13694400000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -12360100000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -3420800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 35931500000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -2991200000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -1334300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 19353000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 9600000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 5551300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 6560500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 226600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 34066600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Normalized Income: 15906218040.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 32660800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Operating Income: 25723500000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 105623100000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 3040000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 1300000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 66869200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 45828200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 610500000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 2537000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 150000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 10000000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 323700000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 5630200000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 3844300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 2846100000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 2469300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1688600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Other Special Charges: -883600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Payables: 26455400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 1130900000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Pretax Income: 23521100000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 70800000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: 0.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: 0.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -4327800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 6431200000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 27877300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 7953000000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -13694400000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Research And Development: 247300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 38600000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 39424000000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 1181000000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 1336600000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 11296800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 19019600000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 338445440.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Short Term Debt Payments: -1334300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Special Income Charges: 753900000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 68561500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 19353000000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 276218040.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Tax Provision: 6957300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.30
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 950700000.00
TORNTPHARM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -4981000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 150605800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 84599300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 40219400000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 68561500000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Total Expenses: 79899600000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 82044300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 94491000000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 27791800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 9300000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 1679300000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 933800000.00
TORNTPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 933800000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 1409500000.00
TORNTPHARM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 1862300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 21880000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 17830000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 650000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 780000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 1690000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 11460000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 14830000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 1690000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 75040000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 4120000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 58790000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 180000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 16340000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 16520000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 48470000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 4350000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 3390000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 46730000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 36290000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 22710000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 105520000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 650000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 600000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 14140000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 14740000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 4460000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 19020000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 36290000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 28310000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 5810000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 7930000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 3380000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 1770000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 73350000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 43340000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 330000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 10000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 32170000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 40000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 3370000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 22790000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 75040000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 28310000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 150880000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 89180000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 31260000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 75040000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 75840000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 92090000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 27370000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 910000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 10320000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 55067000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 14150000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 113172500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 29090000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 18200200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 18200200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 18664500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 18664500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -22393200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -22393200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -122400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -122400000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Amortization: 5427100000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 5427100000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 445700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 445700000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 338445440.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 338545207.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Basic EPS: 56.47
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 14.71
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 8351400000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 17217200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 17217200000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -6118700000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 1762300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 1762300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 5734800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 5734800000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 6879700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 6879700000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -10830300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 2315200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 2315200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 3419600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 3419600000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -2621800000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 937800000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Payable: -2777300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -348000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -4809300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -2529300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 75906900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 75906900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 4090900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 4090900000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 28844900000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 7310000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 56225700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 56225700000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 303700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 303700000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt: 18343400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 18343400000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 18647100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 18647100000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 47171900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 47171900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 4081300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 4081300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation: 7949300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 7949300000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 7949300000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 2010000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 2522200000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 2010000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Derivative Product Liabilities: 5500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 5500000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 338445440.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 338545207.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 56.47
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 14.71
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 4980000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 49300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 49300000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — EBIT: 29241900000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — EBIT: 7210000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — EBITDA: 37191200000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 9220000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -87300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 5734800000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Financial Assets: 48400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets: 48400000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -22979900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 16826300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 16826300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 19732400000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -167300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -13400000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 7382200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill: 3388800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 3388800000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 46021300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 46021300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 18786900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 18786900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 61040600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 61040600000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Gross Profit: 84327600000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 21780000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 53000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 53000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 0.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense: 2513800000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 560000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 2513800000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 560000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Interest Income: 201900000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 201900000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -2622200000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 202600000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Inventory: 25412500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 25412500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 106167800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 106167800000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -5400500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Investment Properties: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investment Properties: 0.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 445700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 445700000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 0.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 7805000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 7805000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 1458600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 1458600000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 11917500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 11917500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 13376100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 13376100000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 0.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -5291800000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 5012700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 5012700000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 28938100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 28938100000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 0.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 0.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Net Debt: 24526100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 24526100000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -147000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Income: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income: 4980000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 4980000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 4980000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 4980000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 4980000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 26728100000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 19112500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 4980000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Interest Income: -2321200000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -560000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 337900000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -9255000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -5291800000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -2321200000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -560000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 38647400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 38647400000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -5941000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -3963200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 29885600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 29885600000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 4600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 4600000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 5941500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 5941500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 8287200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 8287200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 227400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 227400000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 37252600000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 9460000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Normalized Income: 19156405384.22
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 5159729323.31
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 25851100000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Operating Income: 29260600000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 7630000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 113172500000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 29090000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 3360000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 3360000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 1360000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 1360000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 74214600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 74214600000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 42632500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 42632500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 631900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 631900000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 2321200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 420000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 420000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 16200000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -180000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 5689200000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 7030000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 4325800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 4325800000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 2989400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 2989400000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 2594300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 2594300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 1144900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 1144900000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Other Special Charges: 228700000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Other Special Charges: 240000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Payables: 23531000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 23531000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 1351500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 1351500000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Pretax Income: 26728100000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 6650000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 17700000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -117500000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -6118700000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 6282400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 6282400000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 28844900000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 7310000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 7949300000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 2010000000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -9255000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Research And Development: 304200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 49300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 49300000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 455400000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 177700000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 12606700000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 19988900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 338445440.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Short Term Debt Payments: -3963200000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Special Income Charges: -228700000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -240000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 75906900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 75906900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 29885600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 29885600000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -17494615.78
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -60270676.69
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Tax Provision: 7615600000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 1670000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.28
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.25
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 1220900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 1220900000.00
TORNTPHARM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -6028200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 149897400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 149897400000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 87824400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 87824400000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 32023200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 32023200000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 75906900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 75906900000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Total Expenses: 83911900000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 21460000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 73990500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 73990500000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 93671700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 93671700000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 26818600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 26818600000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 9300000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 955700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 955700000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -61400000.00
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -240000000.00
TORNTPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -61400000.00